TY - JOUR
AU1 - Karron, Ruth A.
AU2 - Wright, Peter F.
AU3 - Newman, Frances K.
AU4 - Makhene, Mamodikoe
AU5 - Thompson, Juliette
AU6 - Samorodin, Roberta
AU7 - Wilson, Modena H.
AU8 - Anderson, Edwin L.
AU9 - Clements, Mary Lou
AU1 - Murphy, Brian R.
AU1 - Belshe, Robert B.
AB - The safety, infectivity, immunogenicity, and phenotypic stability of the cold-passaged (cp) candidate vaccine cp-45, a cold-adapted (ca), temperature-sensitive (ts) mutant of the J8 strain of human parainfluenza virus type 3 (HPIV-3), was evaluated in 114 children 6 months to 10 years old in a randomized, placebo-controlled, double-blind trial. The cp-45 vaccine was well tolerated when given intranasally to parainfluenza virus type 3 (PIV-3)-seropositive and -seronegative children. With 104 or 105 TCID50 of cp-45 vaccine, 86% of seronegative vaccinees were infected, 83% of whom shed virus at a mean peak titer of 102.2 pfu/mL. Virus present in respiratory specimens retained the ts phenotype, and each of 86 PIV-3 isolates tested retained both the ca and ts phenotypes. One dose of 105 TCID50 of vaccine induced a serum hemagglutination-inhibiting antibody response in 81% of vaccinees; the geometric mean titer was 1:32. These studies indicate that the cp-45 HPIV-3 vaccine is satisfactorily attenuated, infectious, immunogenic, and phenotypically stable and merits further evaluation in infants and young children.
TI - A Live Human Parainfluenza Type 3 Virus Vaccine Is Attenuated and Immunogenic in Healthy Infants and Children
JF - The Journal of Infectious Diseases
DO - 10.1093/infdis/172.6.1445
DA - 1995-12-01
UR - https://www.deepdyve.com/lp/oxford-university-press/a-live-human-parainfluenza-type-3-virus-vaccine-is-attenuated-and-WlbgkNzmzu
SP - 1445
EP - 1450
VL - 172
IS - 6
DP - DeepDyve
ER -